Summary

Market Size & Trends

The Europe at-home respiratory care services market size was estimated at USD 15.24 billion in 2024 and is projected to reach USD 31.15 billion by 2033, growing at a CAGR of 8.42% from 2025 to 2033. Technological advancements in medical devices, such as the development of smart inhalers, connected nebulizers, and integrated mobile applications, have revolutionized traditional methods of respiratory management.

For instance, in February 2024, Aptar Pharma, a global provider of drug delivery systems and active material science solutions, launched HeroTracker Sense, an innovative digital respiratory health solution designed to convert traditional pressurized metered dose inhalers (pMDIs) into smart, connected healthcare devices. This cutting-edge technology enables real-time monitoring and data-driven management of respiratory conditions, enhancing treatment adherence and supporting more personalized patient care.

The rising prevalence of chronic respiratory diseases is driving the growth of at-home respiratory care services across Europe. According to a European Respiratory Society article, approximately 36.6 million people in Europe were living with chronic obstructive pulmonary disease (COPD) in 2020, with projections indicating a rise to 49.45 million by 2050, equivalent to a 9.3% prevalence.

Conditions such as chronic obstructive pulmonary disease (COPD), asthma, and sleep apnea are increasingly affecting the population, requiring long-term and often continuous respiratory support. These chronic respiratory conditions significantly affect patients’ daily functioning and contribute to increased pressure on national healthcare systems, particularly through elevated hospital admission rates and greater demands on healthcare resources.

Moreover, a growing elderly demographic across Europe is leading to higher incidences of chronic respiratory diseases, increasing the demand for home-based respiratory care. As per the United Nations Population Division report, the share of population aged 65 and above has significantly increased in recent years in Europe, reaching approximately 19.8% in 2023.

Furthermore, the rapid expansion of telehealth and digital health tools is transforming at-home respiratory care services in Europe. Telehealth enables remote consultations, monitoring, and clinical follow-up via digital platforms, reducing the need for physical hospital visits. During the COVID-19 pandemic, the adoption of telemedicine became integral to managing chronic respiratory patients safely at home. In the UK, the NHS launched large-scale remote monitoring initiatives between 2020 and 2023, supporting over 487,000 people at home, including those with COPD and heart failure. Home-based digital tools increased patients’ access improved self-management, and lessened pressure on traditional healthcare facilities.

In addition, empowering patients through education, digital self-management tools, and patient-centered service models is influencing market growth. Initiatives across Europe aim to equip individuals and caregivers with the necessary knowledge and digital resources to effectively manage respiratory conditions at home. For instance, the NHS has invested in tele-coaching, self-care apps, and remote education modules for respiratory patients, which promote adherence and improve disease outcomes.

Europe At-Home Respiratory Care Services Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Europe at-home respiratory care services market report based on therapy, indication, and region:

• Therapy Outlook (Revenue, USD Billion, 2021 - 2033)
• Oxygen therapy
• Non-invasive ventilation
• Sleep apnea care
• Aerosol therapy and others
• Indication Outlook (Revenue, USD Billion, 2021 - 2033)
• Chronic Obstructive Pulmonary Disease (COPD)
• Sleep apnea (obstructive and central types)
• Asthma
• Post-acute respiratory failure

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Definitions
1.2. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.4.6. Research Assumption
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Data Visualization
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. Objectives
1.8.1. Objective - 1
1.8.2. Objective - 2
1.8.3. Objective - 3
1.9. List of Secondary Sources
1.10. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Europe At-Home Respiratory Care Services Market
2.1.1. Market Snapshot
2.1.2. Segment Snapshot
2.1.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing prevalence of chronic respiratory diseases and growing aging population
3.2.1.2. Rising telehealth and digital health adoption
3.2.1.3. Growing patient empowerment and engagement programs
3.2.2. Market Restraint Analysis
3.2.2.1. Safety concerns and improper usage in home settings
3.2.2.2. Economic pressures and infrastructure gaps
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenges Analysis
3.3. Business Environment Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
Chapter 4. Therapy Business Analysis
4.1. Europe At-Home Respiratory Care Services Market: Therapy Movement Analysis
4.2. Europe At-Home Respiratory Care Services Market: Therapy Segment Dashboard
4.3. Therapy Movement & Market Share Analysis, 2024 & 2033
4.4. Europe At-Home Respiratory Care Services Market Estimates & Forecast, by Therapy
4.5. Oxygen Therapy
4.5.1. Oxygen Therapy Market, 2021 - 2033 (USD Billion)
4.6. Non-Invasive Ventilation
4.6.1. Non-Invasive Ventilation Market, 2021 - 2033 (USD Billion)
4.7. Sleep Apnea Care
4.7.1. Sleep Apnea Care Market, 2021 - 2033 (USD Billion)
4.8. Aerosol Therapy and Others
4.8.1. Aerosol Therapy and Others Market, 2021 - 2033 (USD Billion)
Chapter 5. Indication Business Analysis
5.1. Europe At-Home Respiratory Care Services Market: Indication Movement Analysis
5.2. Europe At-Home Respiratory Care Services Market: Indication Segment Dashboard
5.3. Indication Movement & Market Share Analysis, 2024 & 2033
5.4. Europe At-Home Respiratory Care Services Market Estimates & Forecast, by Indication
5.5. Chronic Obstructive Pulmonary Disease (COPD)
5.5.1. Chronic Obstructive Pulmonary Disease (COPD) Market, 2021 - 2033 (USD Billion)
5.6. Sleep Apnea (obstructive and central types)
5.6.1. Sleep Apnea (obstructive and central types) Market, 2021 - 2033 (USD Billion)
5.7. Asthma
5.7.1. Asthma Market, 2021 - 2033 (USD Billion)
5.8. Post-Acute Respiratory Failure
5.8.1. Post-Acute Respiratory Failure Market, 2021 - 2033 (USD Billion)
Chapter 6. Competitive Landscape
6.1. Company Categorization
6.2. Participant’s Overview
6.3. Company Market Position Analysis
6.4. Strategy Mapping
6.4.1. Regional Expansion
6.4.2. Mergers & Acquisitions
6.4.3. Others
6.5. Company Profiles/Listing
6.5.1. Linde Healthcare
6.5.1.1. Overview
6.5.1.2. Financial performance
6.5.1.3. Service benchmarking
6.5.1.4. Strategic initiatives
6.5.2. Bastide Group
6.5.2.1. Overview
6.5.2.2. Financial performance
6.5.2.3. Service benchmarking
6.5.2.4. Strategic initiatives
6.5.3. Vivisol (SOL Group)
6.5.3.1. Overview
6.5.3.2. Financial performance
6.5.3.3. Service benchmarking
6.5.3.4. Strategic initiatives
6.5.4. SOS Oxygène
6.5.4.1. Overview
6.5.4.2. Financial performance
6.5.4.3. Service benchmarking
6.5.4.4. Strategic initiatives
6.5.5. Air Liquide Healthcare
6.5.5.1. Overview
6.5.5.2. Financial performance
6.5.5.3. Service benchmarking
6.5.5.4. Strategic initiatives